Altered DNA damage response (DDR) has emerged as an important mechanism for the development of aggressive prostate cancer among men of European ancestry but not other ancestry groups. Because common mechanisms for aggressive disease are expected, we explored a large panel of DDR genes and pathways to demonstrate that DDR alterations contribute to development of […]
PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated potential in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here, we describe the design and rationale of the multinational, Phase III, two-part TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide as a first-line treatment for patients with mCRPC with or without DNA damage […]
To evaluate the association between intravesicular prostate protrusion (IPP) and the detection rate of clinically significant prostate cancer (csPCa) on MRI TRUS fusion targeted biopsy (TB). 538 consecutive men who underwent MRI TRUS fusion TB and concomitant systematic biopsy were evaluated.
The aim of this study is to evaluate the influence of endogenous testosterone density (ETD) on features of aggressive prostate cancer (PCa) in intermediate-risk disease treated with radical prostatectomy and extended pelvic lymph node dissection.
To examine practice-level variation in the management of MRI PI-RADS 3 lesions in men with favorable-risk prostate cancer (FRPC) considering or on active surveillance (AS). We reviewed the MUSIC registry for FRPC men (GG1 and low-volume GG2) undergoing MRI from 1/2013-3/2020.
Muscle Invasive bladder cancer is known to have an abundance of mutations, particularly in DNA damage response and chromatin modification genes. The role of these mutations in the development and progression of the disease is not well understood.
Introduction: Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies being approved across multiple tumor types, it is essential to define unique clinical hallmarks of these agents and their associated […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute. I am so excited to have here with me today, Dr. Phillip Abbosh who is an Assistant Professor at Fox Chase and Albert Einstein Medical Centers, as well as a Urologic Oncologist and a Translational Bladder […]
Reno, Nevada (UroToday.com) — Lantheus Holdings, Inc. announced that its subsidiary, EXINI Diagnostics AB, has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.
KEYTRUDA Is Now Approved as Monotherapy for Adults With RCC at Increased Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions KEYTRUDA Is the First Immunotherapy Approved in Europe in the Adjuvant Setting for These Patients With RCC Reno, Nevada (UroToday.com) — Merck, known as MSD outside the United States and Canada, […]
